Search

Your search keyword '"Shoumariyeh, Khalid"' showing total 8 results
Start Over Author "Shoumariyeh, Khalid" Publication Year Range This year
8 results on '"Shoumariyeh, Khalid"'

1. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

Author

Maas-Bauer, Kristina, Stell, Anna-Verena, Yan, Kai-Li, de Vega, Enrique, Vinnakota, Janaki Manoja, Unger, Susanne, Núñez, Nicolas, Norona, Johana, Talvard-Balland, Nana, Koßmann, Stefanie, Schwan, Carsten, Miething, Cornelius, Martens, Uta S., Shoumariyeh, Khalid, Nestor, Rosa P., Duquesne, Sandra, Hanke, Kathrin, Rackiewicz, Michal, Hu, Zehan, El Khawanky, Nadia, Taromi, Sanaz, Andrlova, Hana, Faraidun, Hemin, Walter, Stefanie, Pfeifer, Dietmar, Follo, Marie, Waldschmidt, Johannes, Melchinger, Wolfgang, Rassner, Michael, Wehr, Claudia, Schmitt-Graeff, Annette, Halbach, Sebastian, Liao, James, Häcker, Georg, Brummer, Tilman, Dengjel, Joern, Andrieux, Geoffroy, Grosse, Robert, Tugues, Sonia, Blazar, Bruce R., Becher, Burkhard, Boerries, Melanie, and Zeiser, Robert

Published
2024
Full Text
View/download PDF

2. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

Author

Lübke, Johannes, Christen, Deborah, Schwaab, Juliana, Kaiser, Anne, Naumann, Nicole, Shoumariyeh, Khalid, Jentzsch, Madlen, Sockel, Katja, Schaffrath, Judith, Ayuk, Francis A., Stelljes, Matthias, Hilgendorf, Inken, Sala, Elisa, Kaivers, Jennifer, Schönland, Stefan, Wittke, Christoph, Hertenstein, Bernd, Radsak, Markus, Kaiser, Ulrich, Brückl, Valeska, Kröger, Nicolaus, Brümmendorf, Tim H., Hofmann, Wolf-Karsten, Klein, Stefan, Jost, Edgar, Reiter, Andreas, and Panse, Jens

Published
2024
Full Text
View/download PDF

3. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Author

Lübke, Johannes, Schmid, Alicia, Christen, Deborah, Oude Elberink, Hanneke N. G., Span, Lambert F. R., Niedoszytko, Marek, Gorska, Aleksandra, Lange, Magdalena, Gleixner, Karoline V., Hadzijusufovic, Emir, Stefan, Alex, Angelova-Fischer, Irena, Zanotti, Roberta, Bonifacio, Massimiliano, Bonadonna, Patrizia, Shoumariyeh, Khalid, von Bubnoff, Nikolas, Müller, Sabine, Perkins, Cecelia, Elena, Chiara, Malcovati, Luca, Hagglund, Hans, Mattsson, Mattias, Parente, Roberta, Varkonyi, Judit, Fortina, Anna Belloni, Caroppo, Francesca, Brockow, Knut, Zink, Alexander, Breynaert, Christine, Leven, Toon, Yavuz, Akif Selim, Doubek, Michael, Sabato, Vito, Schug, Tanja, Hartmann, Karin, Triggiani, Massimo, Gotlib, Jason, Hermine, Olivier, Arock, Michel, Kluin-Nelemans, Hanneke C., Panse, Jens, Sperr, Wolfgang R., Valent, Peter, Reiter, Andreas, and Schwaab, Juliana

Published
2024
Full Text
View/download PDF

4. Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

Author

Shoumariyeh, Khalid, Csernalabics, Benedikt, Salimi Alizei, Elahe, Reinscheid, Matthias, Giese, Sebastian, Ciminski, Kevin, Kochs, Georg, Schwemmle, Martin, Lang-Meli, Julia, Maas, Michelle, Roehlen, Natascha, Karl, Vivien, Graeser, Anne, Sogukpinar, Oezlem, von Metzler, Ivana, Grathwohl, Denise, Rasche, Leo, Hebart, Holger, Kull, Miriam, and Emmerich, Florian

Subjects
IMMUNOLOGIC memory, HUMORAL immunity, T cells, VACCINATION status, IMMUNODEFICIENCY
Abstract

Background: Multiple myeloma (MM) patients are at high risk of severe infections including COVID-19 due to an immune dysregulation affecting both innate and adaptive immune responses. However, our understanding of the immune responses to infection and vaccination in MM patients is limited. To gain more detailed insights into infection- and vaccine-elicited T cell immunity in MM, we studied the CD8+ T cell response on the single-epitope level in SARS-CoV-2 convalescent and mRNA-vaccinated MM patients. Methods: We compared peptide/MHC class I tetramer-enriched SARS-CoV-2-specific CD8+ T cells and antibody responses in MM patients (convalescent: n = 16, fully vaccinated: n = 5, vaccinated convalescent: n = 5) and healthy controls (HCs) (convalescent: n = 58, fully vaccinated: n = 7) either after infection with SARS-CoV-2 alone, complete mRNA vaccination or SARS-CoV-2 infection and single-shot mRNA vaccination (hybrid immunity). Results: MM patients have lower frequencies and a lower proportion of fully functional virus-specific CD8+ T cells compared to HCs, after both SARS-CoV-2 infection and vaccination. CD8+ T cell memory subset distribution in MM patients is skewed towards reduced frequencies of central memory (TCM) T cells and higher frequencies of effector memory 1 (TEM1) T cells. In contrast, the humoral immune response was comparable in both cohorts after viral clearance. Notably, CD8+ T cell frequencies as well as the humoral immune response were improved by a single dose of mRNA vaccine in convalescent MM patients. Conclusions: MM patients have relative immunological deficiencies in SARS-CoV-2 immunity but benefit from hybrid immunity. These findings underline the relevance of vaccinations in this vulnerable patient group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

Author

Niedoszytko, Marek, primary, Gorska, Aleksandra, additional, Brockow, Knut, additional, Bonadonna, Patrizia, additional, Lange, Magdalena, additional, Kluin‐Nelemans, Hanneke, additional, Oude‐Elberink, Hanneke, additional, Sabato, Vito, additional, Shoumariyeh, Khalid, additional, von Bubnoff, Dagmar, additional, Müller, Sabine, additional, Illerhaus, Anja, additional, Doubek, Michael, additional, Angelova‐Fischer, Irena, additional, Hermine, Olivier, additional, Arock, Michel, additional, Elena, Chiara, additional, Malcovati, Luca, additional, Yavuz, Akif Selim, additional, Schug, Tanja Daniela, additional, Fortina, Anna Belloni, additional, Judit, Várkonyi, additional, Gotlib, Jason, additional, Panse, Jens, additional, Vucinic, Vladan, additional, Reiter, Andreas, additional, Schwaab, Juliana, additional, Triggiani, Massimo, additional, Mattsson, Mattias, additional, Breynaert, Christine, additional, Romantowski, Jan, additional, Zanotti, Roberta, additional, Olivieri, Elisa, additional, Zink, Alexander, additional, van de Ven, Annick, additional, Stefan, Alex, additional, Barete, Stephane, additional, Caroppo, Francesca, additional, Perkins, Cecelia, additional, Kennedy, Vanessa, additional, Christen, Deborah, additional, Jawhar, Mohamad, additional, Luebke, Johannes, additional, Parente, Roberta, additional, Levedahl, Kerstin, additional, Hadzijusufovic, Emir, additional, Hartmann, Karin, additional, Nedoszytko, Boguslaw, additional, Sperr, Wolfgang R., additional, and Valent, Peter, additional

Published
2024
Full Text
View/download PDF

6. MPN-334 Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (AdvSM): Results From Part 1 of the Phase 2 Apex Trial

Author

Vachhani, Pankit, Tashi, Tsewang, Schiller, Gary, Lee, Stephanie, Piris-Villaespesa, Miguel, Pomares, Helena, Bulai Livideanu, Cristina, Lambert, Jonathan, Hunter, Anthony M., George, Tracy I., Patel, Jay, DeAngelo, Daniel J., Papayannidis, Cristina, Shoumariyeh, Khalid, Exter, Ben, Sun, Lei, Zhang, Jenna, Cable, LouAnn, Pilla, Amanda, Jolin, Hina A., Easton, Rachael, Carden, Marcus, and Pullarkat, Vinod

Published
2024
Full Text
View/download PDF

7. Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (AdvSM): Results From Part 1 of the Phase 2 Apex Trial

Author

Vachhani, Pankit, Tashi, Tsewang, Schiller, Gary, Lee, Stephanie, Piris-Villaespesa, Miguel, Pomares, Helena, Bulai Livideanu, Cristina, Lambert, Jonathan, Hunter, Anthony M., George, Tracy I., Patel, Jay, DeAngelo, Daniel J., Papayannidis, Cristina, Shoumariyeh, Khalid, Exter, Ben, Sun, Lei, Zhang, Jenna, Cable, LouAnn, Pilla, Amanda, Jolin, Hina A., Easton, Rachael, Carden, Marcus, and Pullarkat, Vinod

Published
2024
Full Text
View/download PDF

8. Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.

Author

Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, Staehle HF, Vinnakota JM, Duquesne S, Mozaffari Jovein M, Pfeifer D, Becker H, Blazar BR, Zähringer A, Duyster J, Brummer T, Boerries M, Baumeister J, Shoumariyeh K, Li J, Green AR, Heidel FH, Tirosh I, Pahl HL, Leimkühler N, Köhler N, de Toledo MAS, Koschmieder S, and Zeiser R

Subjects
Animals, Humans, Mice, Transforming Growth Factor beta metabolism, Bone Marrow immunology, Bone Marrow metabolism, Tumor Escape immunology, Mice, Inbred C57BL, Transforming Growth Factor beta1 metabolism, Mutation, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory metabolism, Calreticulin metabolism, Myeloproliferative Disorders immunology, Myeloproliferative Disorders metabolism, Myeloproliferative Disorders pathology, Tumor Microenvironment immunology
Abstract

Increasing evidence supports the interplay between oncogenic mutations and immune escape mechanisms. Strategies to counteract the immune escape mediated by oncogenic signaling could provide improved therapeutic options for patients with various malignancies. As mutant calreticulin (CALR) is a common driver of myeloproliferative neoplasms (MPN), we analyzed the impact of oncogenic CALRdel52 on the bone marrow (BM) microenvironment in MPN. Single-cell RNA sequencing revealed that CALRdel52 led to the expansion of TGFβ1-producing erythroid progenitor cells and promoted the expansion of FoxP3+ regulatory T cells (Treg) in a murine MPN model. Treatment with an anti-TGFβ antibody improved mouse survival and increased the glycolytic activity in CD4+ and CD8+ T cells in vivo, whereas T-cell depletion abrogated the protective effects conferred by neutralizing TGFβ. TGFβ1 reduced perforin and TNFα production by T cells in vitro. TGFβ1 production by CALRdel52 cells was dependent on JAK1/2, PI3K, and ERK activity, which activated the transcription factor Sp1 to induce TGFβ1 expression. In four independent patient cohorts, TGFβ1 expression was increased in the BM of patients with MPN compared with healthy individuals, and the BM of patients with MPN contained a higher frequency of Treg compared with healthy individuals. Together, this study identified an ERK/Sp1/TGFβ1 axis in CALRdel52 MPNs as a mechanism of immunosuppression that can be targeted to elicit T-cell-mediated cytotoxicity. Significance: Targeting the mutant calreticulin/TGFβ1 axis increases T-cell activity and glycolytic capacity, providing the rationale for conducting clinical trials on TGFβ antagonists as an immunotherapeutic strategy in patients with myeloproliferative neoplasms., (©2024 American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results